Literature DB >> 8505491

Rate of iron reaccumulation following iron depletion in hereditary hemochromatosis. Implications for venesection therapy.

P C Adams1, A E Kertesz, L S Valberg.   

Abstract

Although venesection therapy is well established for the initial depletion of iron stores in hereditary hemochromatosis, the frequency of subsequent therapy has not been clearly defined. In this study, 21 homozygotes (16 male, five female; mean age of 58, with a range of 26 to 77 years) who had completed initial venesection therapy were followed without further venesections for a mean of 4.0 years (range of 1 to 10.4 years) with iron reaccumulation assessed by annual serum ferritin concentration. Over the follow-up period, the mean rise in serum ferritin was 99 (micrograms/l)/year (range of 1.2 to 241 micrograms/l). The mean interval for the ferritin to become elevated above the normal range in 10 patients was 3.8 years. Eleven of 21 patients required no further venesection therapy over the follow-up interval. There was no significant correlation between the annual rate of ferritin increase and the age or amount of iron removed by prior venesections. These data demonstrate that monitoring body iron stores annually and the selective use of venesections if iron stores reaccumulate is a safe alternative to lifelong venesections every 2-4 months. Many homozygotes will not require reinitiation of venesection therapy for > 4 years. Annual monitoring of body iron stores with reinstitution of weekly venesection when the serum ferritin exceeds the upper limit of normal was a safe alternative to long-term maintenance venesection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8505491     DOI: 10.1097/00004836-199304000-00008

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  7 in total

1.  A duodenal mucosal abnormality in the reduction of Fe(III) in patients with genetic haemochromatosis.

Authors:  K B Raja; D Pountney; A Bomford; R Przemioslo; D Sherman; R J Simpson; R Williams; T J Peters
Journal:  Gut       Date:  1996-05       Impact factor: 23.059

Review 2.  The myths and realities of hemochromatosis.

Authors:  Melanie D Beaton; Paul C Adams
Journal:  Can J Gastroenterol       Date:  2007-02       Impact factor: 3.522

Review 3.  Hepatic iron overload and hepatocellular carcinoma.

Authors:  Michael C Kew
Journal:  Liver Cancer       Date:  2014-03       Impact factor: 11.740

Review 4.  Hereditary Hemochromatosis: A Cardiac Perspective.

Authors:  Pranay K Joshi; Saawan C Patel; Devarashetty Shreya; Diana I Zamora; Gautami S Patel; Idan Grossmann; Kevin Rodriguez; Mridul Soni; Ibrahim Sange
Journal:  Cureus       Date:  2021-11-29

5.  Ferritin Increase in Hemochromatosis Subjects After Discontinuing Their Regular Maintenance Treatment: A Longitudinal Analysis Performed During the COVID-19 Imposed Hospital Lockdown.

Authors:  Maria P Coutinho; Maria José Teles; Graça Melo; Marta Lopes; Delfim Duarte; Tiago L Duarte; Júlia Reis; Ana Cláudia Martins; José Carlos Oliveira; Graça Porto
Journal:  Hemasphere       Date:  2022-08-23

6.  Management of cardiac hemochromatosis.

Authors:  Wilbert S Aronow
Journal:  Arch Med Sci       Date:  2017-06-30       Impact factor: 3.318

7.  The effect of a natural polyphenol supplement on iron absorption in adults with hereditary hemochromatosis.

Authors:  Simone Buerkli; Laura Salvioni; Natalie Koller; Christophe Zeder; Maria José Teles; Graça Porto; Jana Helena Habermann; Irina Léa Dubach; Florence Vallelian; Beat M Frey; Diego Moretti; Jeannine Baumgartner; Michael B Zimmermann
Journal:  Eur J Nutr       Date:  2022-03-23       Impact factor: 4.865

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.